News | Iris Pharma announces facilities expansion

Iris Pharma announces facilities expansion

Nice, France – December 27, 2007 – Due to the steady increase in demand for its services, Iris Pharma has decided to expand its preclinical testing facility.
Expansion will begin in January 2008, increasing by nearly 30% the size of the existing facility and by 46% the housing capacity. The new rooms will support the growing number of demands for ocular preclinical studies. This decision is essential for Iris Pharma to keep guaranteeing and even to improve the high level of flexibility, responsiveness and service quality it offers to its clients today.
Pierre-Paul Elena, President and Chief Executive Officer for Iris Pharma, said: “We are extremely excited about the housing facility expansion plan. This is the result of a continuous growth over the past several years and a proof of confidence from our sponsors in Iris Pharma’s services and expertise. This decision to expand is in keeping with our general objectives: to provide our clients with the best quality services for the greatest satisfaction. With this expansion we will ensure room availability and fast study starts to meet our customers’ needs for the near term and into the future.”
The housing facility expansion should be completed by the end of first quarter 2008. Like the existing housing facility the new rooms will be designed according to Iris Pharma’s values: animal welfare and respect for the environment.

About Iris Pharma:
Iris Pharma is an independant CRO headquartered in Nice, France, dedicated to pre-clinical and clinical research in ophthalmology. Created in 1989, it provides drug development services to Research Institutes, Pharmaceutical or Biotechnology Industries. It today groups four areas of complementary activities: bioanalysis and pre-clinical formulation, pre-clinical studies and services, clinical trials, and strategic consulting. Iris Pharma has been selected by the European Vision Institute Clinical Trials Sites of Excellence, a network of European ophthalmic clinical research sites, as an independent expert for optimizing their network consolidation through consulting, site audits, and certification.
For more information, see: